8-K: Precigen Secures Key Manufacturing Deal with Catalent

Precigen, Inc. has entered into a multi-year exclusive commercial supply agreement with Catalent Maryland, Inc. for the fill and finish manufacturing of its PRGN-2012 product.

Summary

• Precigen, Inc. (the Company) entered into a Commercial Supply Agreement (the Supply Agreement) with Catalent Maryland, Inc. (Catalent) on August 13, 2025.
• Catalent will provide services including analytical, development, processing, validation, or product maintenance for Precigen's PRGN-2012 product (PAPIZEMOS).
• Precigen has agreed to exclusively use Catalent for external, commercial fill and finish manufacturing of all reported volumes of PRGN-2012 in the Territory (United States and other agreed countries) each calendar year.
• The initial term of the Supply Agreement is three years from the Commencement Date (first Regulatory Authority approval of Catalent as manufacturer), with automatic one-year extensions unless terminated with twelve months' prior notice.
• Precigen must purchase a specified minimum number of batches in contract years, if defined in the Plan Document, or pay the difference.
• Precigen will pay Catalent an agreed-upon price and other fees for services, adjusted annually (effective on each anniversary of the Effective Date) to reflect increases in labor, utilities, and overhead, at least equal to the Producer Price Index (PPI) for Pharmaceutical Preparation Manufacturing, but not exceeding [***] annually.
• Pass-through costs, including raw materials, consumables, testing, shipping, and waste removal, will be reimbursed by Precigen at Catalent's actual costs plus an additional [***] administrative fee.
• If Regulatory Approval for Catalent to commence processing is not obtained within [***] following the Effective Date, Precigen will pay a 'Delayed Approval Fee' until approval is secured.
• The agreement includes customary provisions for delivery, inspection, warranties, quality, storage, intellectual property, confidentiality, and indemnification.

Sentiment

Score: 7

Explanation: The agreement is a positive step for Precigen, securing critical manufacturing capabilities for a key product. However, the exclusivity, minimum purchase obligations, and potential for cost increases introduce financial commitments and risks that warrant a moderately positive sentiment rather than a strong one.

Positives

• Secures exclusive external commercial fill and finish manufacturing for Precigen's PRGN-2012 product, ensuring supply chain stability.
• Establishes a long-term partnership with Catalent, a leading provider of advanced manufacturing services in the pharmaceutical and biotechnology sectors.
• The agreement covers a broad range of services, from analytical and development to processing and product maintenance, providing comprehensive support for PRGN-2012.
• The automatic one-year extensions after the initial three-year term provide continuity and predictability for manufacturing operations.

Negatives

• Precigen is bound by an exclusivity clause for external commercial fill and finish manufacturing of PRGN-2012, limiting options.
• Minimum purchase requirements, if specified, obligate Precigen to pay for unpurchased batches.
• Annual price adjustments for services, tied to PPI and potentially up to [***] annually, could increase manufacturing costs over time.
• Precigen is responsible for all Pass-through Costs, including a [***] administrative fee, which adds to the overall expense.
• A 'Delayed Approval Fee' will be incurred if regulatory approval for Catalent to commence processing is not obtained within [***] of the Effective Date, adding financial risk.

Risks

• Regulatory approval delays for Catalent to commence processing could lead to additional 'Delayed Approval Fees' for Precigen.
• Potential for production delays if Catalent is unable to obtain raw materials in a timely manner, impacting product availability.
• Risk of out-of-specification batches, which, if not attributable to Catalent's negligence or material breach, would require Precigen to bear the cost of replacement batches.
• Costs associated with product recalls will be borne by Precigen unless solely caused by Catalent's gross negligence, willful misconduct, or material breach.
• Intellectual property infringement claims by third parties could arise, requiring either party to procure rights or modify services, potentially leading to agreement termination if not feasible.

Future Outlook

The agreement secures a long-term, exclusive manufacturing partnership for Precigen's PRGN-2012 product, aiming to ensure commercial supply and support its market entry and growth. It outlines a structured framework for ongoing production, quality control, and regulatory compliance.

Industry Context

This agreement is consistent with the common practice in the biotechnology and pharmaceutical industries where companies, particularly those developing advanced therapies like gene therapies, outsource specialized manufacturing processes such as fill and finish to Contract Development and Manufacturing Organizations (CDMOs) like Catalent. This allows companies like Precigen to focus on R&D and commercialization while leveraging the expertise and infrastructure of established manufacturers.

Comparison to Industry Standards

• The exclusivity clause for commercial fill and finish manufacturing is a common feature in strategic CDMO partnerships, ensuring dedicated capacity and expertise for a key product.
• The inclusion of minimum purchase requirements and annual price adjustments based on inflation (PPI) are standard contractual elements in long-term supply agreements to manage cost fluctuations and ensure commitment.
• The detailed provisions for intellectual property ownership, confidentiality, and indemnification align with industry best practices for protecting proprietary information and allocating risk in complex manufacturing collaborations.
• The requirement for both parties to maintain specific insurance coverages (e.g., commercial general liability, products liability) is standard for mitigating risks in pharmaceutical manufacturing.

Stakeholder Impact

• Shareholders: Benefit from secured manufacturing for a key product, reducing supply chain risk and supporting future revenue generation, but face potential financial obligations from exclusivity and minimum purchase requirements.
• Customers: Potential for more reliable and consistent supply of PRGN-2012 once regulatory approvals and manufacturing are fully established.
• Employees: No direct impact on employment mentioned, but stable manufacturing could support long-term company growth.
• Suppliers: Catalent's suppliers of raw materials and components will see increased demand.
• Creditors: The agreement represents a significant operational commitment that could impact cash flow and financial stability, depending on the product's commercial success and associated costs.

Next Steps

• Obtain Regulatory Approval for Catalent as a manufacturer for PRGN-2012 to commence processing.
• Develop and agree upon specific Plan Documents (Commercial Product Plan, Project Plan, or Statement of Work) detailing services, pricing, and schedules.
• Negotiate and enter into a Quality Agreement prior to the first CGMP processing of the product.
• Precigen to provide rolling forecasts and submit binding purchase orders for PRGN-2012 quantities.

Key Dates

Recommendation

Securing a long-term, exclusive manufacturing agreement with a reputable CDMO like Catalent for a key product like PRGN-2012 is a strategic positive, de-risking future supply. However, the financial implications, including minimum purchase commitments, potential for annual price increases, and delayed approval fees, introduce significant obligations. Without specific financial projections for PRGN-2012's market performance and the exact redacted cost percentages, it's difficult to fully assess the net financial impact. The exclusivity also limits Precigen's flexibility. Therefore, a 'hold' recommendation is appropriate, suggesting investors monitor the product's commercial progress and the financial terms' impact on profitability.

Keywords

Precigen, Catalent, PRGN-2012, PAPIZEMOS, commercial supply agreement, manufacturing, fill and finish, gene therapy, biotechnology, pharmaceutical, SEC filing, 8-K, contract manufacturing